var data={"title":"Paliperidone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Paliperidone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/250813?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=paliperidone-drug-information\" class=\"drug drug_general\">see &quot;Paliperidone: Drug information&quot;</a> and <a href=\"topic.htm?path=paliperidone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Paliperidone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50629645\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Atypical Antipsychotics Safety Review</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has reviewed the potential risk of sleep walking and sleep-related eating disorder with the use of atypical antipsychotics and concluded there is a link between these adverse reactions and the use of these medications. Health Canada has recommended to update the product safety information for all atypical antipsychotics to include these adverse reactions.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/atypical-antipsychotics-assessing-potential-risk-sleep-walking-sleep-related-eating-disorder.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709193\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased mortality in elderly patients with dementia-related psychosis: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Paliperidone is not approved for the treatment of patients with dementia-related psychosis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3981432\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Invega;</li>\n      <li>Invega Sustenna;</li>\n      <li>Invega Trinza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5941023\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Invega;</li>\n      <li>Invega Sustenna;</li>\n      <li>Invega Trinza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15513469\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antipsychotic Agent, Benzisoxazole</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Second Generation (Atypical) Antipsychotic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15513477\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=paliperidone-drug-information\" class=\"drug drug_general\">see &quot;Paliperidone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Irritability associated with autistic disorder:</b> Limited data available: Children &ge;12 years and Adolescents: Oral: Extended-release tablet: Initial: 3 mg once daily; titrate on a weekly basis in 3 mg/day increments until clinical response or intolerance; maximum daily dose: 12 mg/<b>day</b>. Dosing based on an open-label trial of 25 patients (mean age: 15.3 years; age range: 12 to 21 years); therapeutic response was reported in 84% of patients at a mean final dose: 7.1 mg/day (Stigler 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizoaffective disorder: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Extended-release tablet: Adolescents &ge;18 years: Usual: 6 mg once daily (administered in the morning in clinical trials); titration not required, though some may benefit from lower or higher doses (range: 3 to 12 mg daily). If exceeding 6 mg daily, increases of 3 mg daily are recommended at intervals of more than 4 days, up to a maximum daily dose: 12 mg/<b>day</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Parenteral: Adolescents &ge;18 years: Monthly paliperidone injection (Invega Sustenna): IM: <b>Note:</b> Prior to initiation of monthly IM paliperidone, patients naive to oral paliperidone or oral or injectable risperidone should have tolerability established with a test dose of oral paliperidone or oral risperidone. Previous oral antipsychotic regimen can be gradually discontinued at the time of initiation of monthly IM paliperidone.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initiation of therapy (2-dose series):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Missed second initiation dose: If the target administration date of 1 week &plusmn; 4 days for the second dose is missed, catch-up dosing depends on the time elapsed since the first dose.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Time elapsed since last first dose</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Catch-up dose for therapy initiation </b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&lt;4 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer the missed dose 156 mg (in the deltoid) as soon as possible, followed by a third dose of 117 mg (in either the deltoid or gluteal muscle) 5 weeks after the first injection (regardless of when the second injection was administered), then begin normal monthly maintenance dosing.</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&ge;4 weeks to &le;7 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer a dose of 156 mg (in the deltoid) as soon as possible, followed by another 156 mg dose (in the deltoid) 1 week later, then begin normal monthly maintenance dosing</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&gt;7 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Reinitiate following dosing recommendations for initiation of therapy</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: First maintenance injection should be administered 5 weeks after the first injection of the initial series. Adjust the dose based on response and tolerability and begin a maintenance dose of 78 to 234 mg (every month administered in either the deltoid or gluteal muscle). The monthly maintenance dose may be administered 7 days before or after the monthly time point.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Missed maintenance dose: Dose and interval dependent upon time since last dose, see table:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Time elapsed since last monthly maintenance injection</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Catch-up dosing</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&ge;4 weeks to &le;6 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer the missed dose as soon as possible and continue therapy at monthly interval</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&gt;6 weeks to &le;6 months and dose &lt;234 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer the same dose the patient was previously stabilized on in the deltoid as soon as possible, followed by a second equivalent dose in the deltoid 1 week later, then resume maintenance dose at monthly intervals.</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&gt;6 weeks to &le;6 months and dose 234 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer a 156 mg dose in the deltoid as soon as possible, followed by a second dose of 156 mg in the deltoid 1 week later, then resume maintenance dose at monthly intervals.</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&gt;6 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Reinitiate following dosing recommendations for initiation of therapy.</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>\n        <i>Conversion from oral extended-release paliperidone to monthly IM paliperidone:</i></i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initiate monthly IM paliperidone as described using the 1-week initiation regimen. Patients previously stabilized on oral doses can expect similar steady state exposure during maintenance treatment with monthly IM paliperidone using the following conversion:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Oral extended release once daily dose</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Monthly maintenance IM dose</b>\n              <b>(Invega Sustenna)</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">39 to 78 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">117 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">156 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">234 mg</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion from other oral antipsychotics to monthly IM paliperidone:</i> There is no systematically collected data to address switching patients from other oral antipsychotics to monthly IM paliperidone.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Switching from other long-acting injectable antipsychotics (at steady-state) to monthly IM paliperidone:</i> Initiate monthly IM paliperidone in the place of the next scheduled injection and continue at monthly intervals; may be administered in the deltoid or gluteal muscle. The two initiation doses are not required in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustments:</i> Adjustments may be made monthly (full effect from adjustments may not be seen for several months)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizophrenia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Extended-release tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 and Adolescents &lt;18 years: 3 mg once daily; titration not necessary; if after clinical assessment a dosage increase is required, may increase dose in 3 mg/day increments at least every 5 days; maximum daily dose is weight dependent: &lt;51 kg: 6 mg/<b>day</b>; &ge;51 kg: 12 mg/<b>day</b>; <b>Note:</b> During adolescent clinical trials, higher doses were not associated with greater efficacy, but increased risk of adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: &ge;18 years: Usual dose: 6 mg once daily (administered in the morning in clinical trials); titration not required, though some may benefit from lower or higher doses (range: 3 to 12 mg daily). If exceeding 6 mg daily, increases of 3 mg daily are recommended no more frequently than every 5 days, up to a maximum of 12 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Parenteral: Adolescents &ge;18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Monthly paliperidone injection (Invega Sustenna):</i> IM: <b>Note:</b> Prior to initiation of monthly IM therapy, tolerability should be established with oral paliperidone or oral risperidone; may require test dose of oral paliperidone or risperidone. Previous oral antipsychotics can be discontinued at the time of initiation of IM therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initiation of therapy (2-dose series):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Missed second initiation dose: If the target administration date of 1 week &plusmn; 4 days for the second dose is missed, catch-up dosing depends on the time elapsed since the first dose.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Time elapsed since last first dose</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Catch-up dose for therapy initiation </b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&lt;4 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer the missed dose of 156 mg (in the deltoid) as soon as possible, followed by a third dose of 117 mg (in either the deltoid or gluteal muscle) 5 weeks after the first injection (regardless of when the second injection was administered), then begin normal monthly maintenance dosing.</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&ge;4 weeks to &le;7 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer a dose of 156 mg (in the deltoid) as soon as possible, followed by another 156 mg dose (in the deltoid) 1 week later, then begin normal monthly maintenance dosing</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&gt;7 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Reinitiate following dosing recommendations for initiation of therapy</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance: First maintenance injection should be administered 5 weeks after the first injection of the initial series. Begin with a maintenance dose 117 mg every month administered in either the deltoid or gluteal muscle. Some patients may benefit from higher or lower monthly maintenance doses (monthly maintenance dosage range: 39 to 234 mg). The monthly maintenance dose may be administered 7 days before or after the monthly time point.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Missed maintenance dose: Dose and interval dependent upon time since last dose, see table:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Time elapsed since last monthly maintenance injection</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Catch-up dosing</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&ge;4 weeks to &le;6 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer the missed dose as soon as possible and continue therapy at monthly interval</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&gt;6 weeks to &le;6 months and dose &lt;234 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer the same dose the patient was previously stabilized on in the deltoid as soon as possible, followed by a second equivalent dose in the deltoid 1 week later, then resume maintenance dose at monthly intervals.</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&gt;6 weeks to &le;6 months and dose 234 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer a 156 mg dose in the deltoid as soon as possible, followed by a second dose of 156 mg in the deltoid 1 week later, then resume maintenance dose at monthly intervals.</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&gt;6 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Reinitiate following dosing recommendations for initiation of therapy.</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from oral paliperidone to IM paliperidone monthly injection</i>: Initiate IM therapy as described using the 1-week initiation regimen. Patients previously stabilized on oral doses can expect similar steady state exposure during maintenance treatment with IM therapy using the following conversion:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Oral extended release once daily dose</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Monthly maintenance IM dose</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">39 to 78 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">117 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">156 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">234 mg</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Switching from other long acting injectable antipsychotics to IM paliperidone</i>: Initiate IM paliperidone in the place of the next scheduled injection and continue at monthly intervals. The 1-week initiation regimen is not required in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosage adjustments</i>: Adjustments may be made monthly (full effect from adjustments may not be seen for several months)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Three-month paliperidone (Invega Trinza):</i> IM: <b>Note:</b> 3-month IM paliperidone is to be used only after monthly IM paliperidone (Invega Sustenna) has been established as adequate treatment for at least 4 months. The last 2 doses of monthly IM paliperidone should be the same dosage strength before starting 3-month IM paliperidone.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from monthly injection and 3-month injection:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Monthly to 3-month injections: Initiate 3-month IM paliperidone when the next monthly IM paliperidone dose is scheduled. Base the 3-month dose on the previous monthly dose, using the equivalent 3.5 times <b>higher</b> dose (see following table). Three-month IM paliperidone may be administered up to 7 days before or after the next monthly dose date. Following the initial injection, administer every 3 months. Patients may be given the injection up to 2 weeks before or after the 3-month time point.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Three-month to monthly injections: Initiate monthly IM paliperidone when the next 3-month IM paliperidone dose is scheduled. Base the monthly dose on the previous 3-month dose, using the equivalent 3.5 times <b>lower </b>dose (see following table). After initial injection, administer once monthly.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Monthly IM paliperidone dose</b></p>\n            <p style=\"text-indent:0em;\">\n              <b>(Invega Sustenna)</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>3-month paliperidone dose</b></p>\n            <p style=\"text-indent:0em;\">\n              <b>(Invega Trinza)</b></p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <b>Note:</b> Conversion from monthly IM paliperidone (Invega Sustenna) 39 mg to 3-month IM paliperidone (Invega Trinza) has not been studied.</p></td></tr></tfoot>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">78 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">273 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">117 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">410 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">156 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">546 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">234 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">819 mg</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from 3-month IM paliperidone to oral paliperidone extended-release tablets:</i> Initiate paliperidone extended-release tablets at least 3 months after the last dose of 3-month IM paliperidone. Base the once daily extended-release tablet dose on the last 3-month injection dose and weeks since last administered. Use the following conversion.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>3-month paliperidone dose</b></p>\n            <p style=\"text-indent:0em;\">\n              <b>(Invega Trinza)</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Time elapsed since last IM dose</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Oral extended release once daily dose</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">273 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;12 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 mg</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">410 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 weeks to &le;24 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;24 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 mg</p></td></tr>\n        <tr>\n          <td rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">546 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to &le;18 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;18 to &le;24 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;24 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9 mg</p></td></tr>\n        <tr>\n          <td rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">819 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to &le;18 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;18 to &le;24 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;24 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 mg</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosage adjustments:</i> Dosage adjustments can be made every 3 months in increments within the range of 273 to 819 mg based on response and tolerability. Due to the long-acting nature, the patient's response to an adjusted dose may not be apparent for several months.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Missed doses:</i> Dose and interval dependent upon time since last dose; use of the monthly dosage form (Invega Sustenna) may be necessary in some cases; see table:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b> Time</b>\n              <b> elapsed since last 3 month maintenance dose</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Catch-up dosing</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">3<sup>1</sup>/<sub>2</sub> months to 4 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer the previous 3-month dose as soon as possible and continue with normal dosing</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\"> 4 months to 9 months and dose 273 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer 78 mg of monthly IM paliperidone (Invega Sustenna) into the deltoid muscle. Repeat same dose of monthly IM paliperidone (Invega Sustenna) 1 week later. One month following the second injection, administer 273 mg of 3-month IM paliperidone (Invega Trinza) into the deltoid or gluteal muscle and resume normal dosing at 3-month intervals</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">4 months to 9 months and dose 410 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer 117 mg of monthly IM paliperidone (Invega Sustenna) into the deltoid muscle. Repeat same dose of monthly IM paliperidone (Invega Sustenna) 1 week later. One month following the second injection, administer 410 mg of 3-month IM paliperidone (Invega Trinza) into the deltoid or gluteal muscle and resume normal dosing at 3-month intervals.</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">4 months to 9 months and dose 546 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer 156 mg of monthly IM paliperidone (Invega Sustenna) into the deltoid muscle. Repeat same dose of monthly IM paliperidone (Invega Sustenna) 1 week later. One month following the second injection, administer 546 mg of 3-month IM paliperidone (Invega Trinza) into the deltoid or gluteal muscle and resume normal dosing at 3-month intervals.</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">4 months to 9 months and dose 819 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Administer 156 mg of monthly IM paliperidone (Invega Sustenna) into the deltoid muscle. Repeat same dose of monthly IM paliperidone (Invega Sustenna) 1 week later. One month following the second injection, administer 819 mg of 3-month IM paliperidone (Invega Trinza) into the deltoid or gluteal muscle and resume normal dosing at 3-month intervals.</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">&gt;9 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">Re-initiate treatment with monthly IM paliperidone (Invega Sustenna). Three-month IM paliperidone can be resumed after the patient has been adequately treated with monthly IM paliperidone for at least 4 months.</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> All patients:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance is decreased in renal impairment; adjust dose according to renal function:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: There are no dosage adjustment provided in the manufacturer's labeling for pediatric patients &le;17 years. For older adolescents the following has been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild impairment (CrCl 50 to 79 mL/minute): Initial dose: 3 mg once daily; maximum dose: 6 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate to severe impairment (CrCl 10 to 49 mL/minute): Initial dose: 1.5 mg once daily; maximum dose: 3 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Severe impairment (CrCl &lt;10 mL/minute): Use not recommended (has not been studied)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: Adolescents &ge;18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild impairment (CrCl 50 to 79 mL/minute):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Monthly IM paliperidone (Invega Sustenna): Initiation of therapy: 156 mg on treatment day 1, followed by 117 mg 1 week later with both doses administered in the deltoid, followed by a maintenance dose of 78 mg every month (administered in the deltoid or gluteal muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Three-month IM paliperidone (Invega Trinza): Adjust dosage and stabilize the patient using the monthly IM injection, then transition to the 3-month IM injection. <b>Note:</b> Monthly IM paliperidone (Invega Sustenna) 78 mg = 3-month IM paliperidone (Invega Trinza) 273 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate to severe impairment (CrCl &lt;50 mL/minute): Use not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients: Oral, IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate (Child-Pugh class A or B): No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982430\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intramuscular, as palmitate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Invega Sustenna: 39 mg/0.25 mL (0.25 mL); 78 mg/0.5 mL (0.5 mL); 117 mg/0.75 mL (0.75 mL); 156 mg/mL (1 mL); 234 mg/1.5 mL (1.5 mL) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Invega Trinza: 410 mg/1.315 mL (1.315 mL); 273 mg/0.875 mL (0.875 mL); 546 mg/1.75 mL (1.75 mL); 819 mg/2.625 mL (2.625 mL) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Invega: 1.5 mg, 3 mg, 6 mg, 9 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.5 mg, 3 mg, 6 mg, 9 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3981434\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15513478\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer in the morning without regard to meals; swallow extended-release tablets whole with liquids; do not crush, chew, or divide.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer only as a single injection (do not divide); do not administer by any other route. Avoid inadvertent injection into vasculature.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Monthly paliperidone (Invega Sustenna): Do not mix with any other product or diluent. Prior to injection, shake syringe for <b>at least 10 seconds</b> to ensure a homogenous suspension. Administer using only the needles that are provided in the kit. The 2 initial injections should be administered in the deltoid muscle using a 1<sup>1</sup>/<sub>2</sub>-inch, 22-gauge needle for patients &ge;90 kg, and a 1-inch, 23-gauge needle for patients &lt;90 kg. The two initial deltoid intramuscular injections help attain therapeutic concentrations rapidly. Alternate deltoid injections (right and left deltoid muscle). The second dose may be administered 4 days before or after the weekly time point. Monthly maintenance doses can be administered in either the deltoid or gluteal muscle. Administer injections in the gluteal muscle using a 1<sup>1</sup>/<sub>2</sub>-inch, 22-gauge needle (regardless of patient weight) in the upper-outer quadrant of the gluteal area. Alternate gluteal injections (right and left gluteal muscle). The monthly maintenance dose may be administered 7 days before or after the monthly time point.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Three-month paliperidone (Invega Trinza): Should only be administered by a health care professional. Prior to injection, shake syringe with tip pointing up for <b>at least 15 seconds</b> to ensure a homogenous suspension. <b>Inject within 5 minutes of shaking vigorously.</b> Inject slowly, deep into the deltoid or gluteal muscle. Must be administered using only the thin wall needles that are provided in the pack. Do <b>not</b> use needles from monthly IM paliperidone or other commercially-available needles to reduce the risk of blockage. Administer into the center of the deltoid muscle using a 1<sup>1</sup>/<sub>2</sub>-inch, 22-gauge thin wall needle for patients &ge;90 kg, and a 1-inch, 22-gauge thin wall needle for patients &lt;90 kg. Alternate deltoid injections (right and left deltoid muscle). Administer injections in the gluteal muscle using a 1<sup>1</sup>/<sub>2</sub>-inch, 22-gauge thin wall needle (regardless of patient weight) in the upper-outer quadrant of the gluteal area. Alternate gluteal injections (right and left gluteal muscle). In the event of an incompletely administered dose, do not re-inject the dose remaining in the syringe and do not administer another dose. Closely monitor and treat the patient with oral supplementation as clinically appropriate until the next scheduled 3-month injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133437\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. For IM preparation, NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator). Double gloving and a protective gown are required during IM administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982397\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral, Monthly IM: Store at &le;25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect tablets from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">3-month IM: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15513470\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment of schizophrenia (FDA approved in ages &ge;12 years and adults); treatment of schizoaffective disorder as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants (FDA approved in adults); has also been used for treatment of irritability associated with autistic disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment of schizophrenia and schizoaffective disorder (monotherapy) and as adjunct to mood stabilizer and antidepressants (Invega Sustenna: FDA approved in ages &ge;18 years and adults); treatment of schizophrenia in patients adequately treated for 4 months with the 1-month paliperidone extended-release formulation (Invega Trinza: FDA approved in ages &ge;18 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14087817\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Invega may be confused with Intuniv</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Antipsychotics are identified in the Beers Criteria  as potentially inappropriate medications to be avoided in patients 65 years and older with dementia due to an increased risk of mortality, cerebrovascular accidents (stroke), and a greater rate of cognitive decline with use; avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. Use <i>may be appropriate</i> in geriatric patients with schizophrenia, bipolar disorder, or for short-term use as an antiemetic during chemotherapy. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982388\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia (adolescents and adults), bundle branch block, cerebrovascular accident, edema (adolescents and adults), first degree atrioventricular block, hypertension, hypotension, ischemia, orthostatic hypotension (dose dependent), palpitations (adolescents and adults), peripheral edema, postural orthostatic tachycardia, prolonged Q-T interval on ECG, sinus arrhythmia, tachycardia (adolescents and adults), transient ischemic attacks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, akathisia (adolescents and adults; dose dependent), anxiety (adolescents and adults), dizziness (adolescents and adults), drooling, drowsiness (more common in adolescents; dose dependent), dysarthria (dose dependent), dystonia (adolescents and adults; dose dependent), extrapyramidal reaction (more common in adolescents; dose dependent), fatigue (adolescents and adults), headache (adolescents and adults), hypertonia, insomnia (adolescents and adults), lethargy (adolescents), nightmares, opisthotonus (adolescents and adults), parkinsonian-like syndrome (adolescents and adults; dose dependent), psychomotor agitation, restlessness, seizure, sleep disorder, tonic-clonic seizures, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Papular rash, pruritus (adolescents and adults), skin rash (adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Abnormal triglycerides (adolescents and adults), altered serum glucose (adolescents and adults), amenorrhea (adolescents and adults), blood cholesterol abnormal (adolescents and adults), decreased HDL cholesterol (adolescents and adults), galactorrhea (adolescents and adults), gynecomastia (adolescents and adults), menstrual disease, weight gain (adolescents and adults; &ge;7% from baseline)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: abdominal pain, constipation, decreased appetite, diarrhea, dyspepsia, flatulence (adolescents and adults), increased appetite, intestinal obstruction, nausea, sialorrhea (adolescents and adults; dose dependent), stomach discomfort, swollen tongue (adolescents), toothache, vomiting (adolescents and adults), xerostomia (adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Breast disease (includes discharge, engorgement, pain, tenderness), erectile dysfunction, retrograde ejaculation (adolescents and adults), sexual disorder, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Change in LDL (adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT (adolescents and adults), increased serum AST (adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis (adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site, injection site reaction, swelling at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: arthralgia (adolescents and adults), back pain, dyskinesia (adolescents and adults), hyperkinesia (adolescents and adults; dose dependent), limb pain, myalgia (dose dependent), neck stiffness, stiffness, tongue paralysis (adolescents), tremor (adolescents and adults), weakness (adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Abnormal eye movements (adolescents and adults), blurred vision (adolescents and adults), oculogyric crisis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Aspiration pneumonia, cough (dose dependent), epistaxis, nasal congestion (adolescents and adults), nasopharyngitis (adolescents and adults; dose dependent), pharyngolaryngeal pain (dose dependent), rhinitis (dose dependent), upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Agranulocytosis, alopecia, antiemetic effect, atrial fibrillation, deep vein thrombosis, diabetes mellitus, diabetic ketoacidosis, hyperprolactinemia, hypothermia, intraoperative floppy iris syndrome, jaundice, mania, neuroleptic malignant syndrome, orthostatic dizziness, pancreatitis, priapism, pulmonary embolism, sedation, SIADH, sleep apnea, syncope, tardive dyskinesia, thrombocytopenia, thrombotic thrombocytopenic purpura, trismus, urinary incontinence, urinary retention, venous thromboembolism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982382\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to paliperidone, risperidone, or any component of the formulation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982383\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: May alter cardiac conduction and prolong the QTc interval; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics (Ray 2009). Risk may be increased by conditions or concomitant medications which cause bradycardia, hypokalemia, and/or hypomagnesemia. Avoid use in combination with QTc-prolonging drugs. Avoid use in patients with congenital long QT syndrome and in patients with history of cardiac arrhythmia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, preexisting low WBC or ANC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Monitor patients with clinically significant neutropenia for a fever or other signs of infection, and discontinue therapy if absolute neutrophil count &lt;1,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular effects: An increased incidence of cerebrovascular adverse effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of risperidone (paliperidone is the primary active metabolite of risperidone) for the unapproved use in elderly patients with dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyslipidemia: Increased cholesterol and triglycerides and decreased HDL have been noted. Use with caution in patients with a pre-existing abnormal lipid profile.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of aspiration pneumonia (eg, Alzheimer disease). Do not use in patients unable to swallow the tablet whole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics; frequencies reported are similar to placebo). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Factors associated with greater vulnerability to tardive dyskinesia include older in age, female gender combined with postmenopausal status, Parkinson disease, pseudoparkinsonism symptoms, affective disorders (particularly major depressive disorder), concurrent medical diseases such as diabetes, previous brain damage, alcoholism, poor treatment response, and use of high doses of antipsychotics (APA [Lehman 2004]; Soares-Weiser 2007). Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability. Complete fall risk assessments at baseline and periodically during treatment in patients with diseases or on medications that may also increase fall risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. All patients should be monitored for symptoms of hyperglycemia (eg, polydipsia, polyuria, polyphagia, weakness). Use with caution in patients with diabetes (or risk factors) or other disorders of glucose regulation; monitor for worsening of glucose control. Patients with risk factors for diabetes (eg, obesity or family history) should have a baseline fasting blood sugar (FBS) and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperprolactinemia: Use is associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intraoperative floppy iris syndrome (IFIS): Few case reports describe IFIS in patients receiving risperidone and undergoing cataract surgery (Ford, 2011). IFIS has not been reported with paliperidone but caution is advised since it is the active metabolite of risperidone. Prior to cataract surgery, evaluate for prior or current paliperidone or risperidone use. The benefits or risks of interrupting paliperidone or risperidone prior to surgery have not been established; clinicians are advised to proceed with surgery cautiously.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability (risk may be increased in patients with Parkinson disease or Lewy body dementia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension and syncope; use with caution in patients with known cardiovascular disease (heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Rare cases of priapism have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.</b> Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Use with caution in patients with Lewy body dementia or Parkinson disease dementia due to greater risk of adverse effects, increased sensitivity to extrapyramidal effects, and association with irreversible cognitive decompensation or death. (APA [Reus 2016]). Paliperidone is not approved for the treatment of dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; may be more sensitive to CNS-related and extrapyramidal effects. Antipsychotics may aggravate motor disturbances in patients with Parkinson disease (APA [Lehman 2004]; APA [Reus 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with mild renal disease; dosage reduction is recommended. Not recommended in patients with moderate to severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release tablet: Use is not recommended in patients with preexisting severe gastrointestinal narrowing disorders (nondeformable controlled release formulation). Patients with upper GI tract alterations in transit time may have increased or decreased bioavailability of paliperidone. Formulation consists of drug within a nonabsorbable shell; following drug release/absorption, the shell is expelled in the stool.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Other warnings/precautions</b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: When discontinuing antipsychotic therapy, the American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid physical withdrawal symptoms, including anorexia, anxiety, diaphoresis, diarrhea, dizziness, dyskinesia, headache, myalgia, nausea, paresthesia, restlessness, tremulousness, and vomiting (APA [Lehman 2004]; CPA [Addington 2005]; Lambert 2007; WFSBP [Hasan 2012]). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). Additional factors such as duration of antipsychotic exposure, the indication for use, medication half-life, and risk for relapse should be considered. In schizophrenia, there is no reliable indicator to differentiate the minority who will not from the majority who will relapse with drug discontinuation. However, studies in which the medication of well-stabilized patients were discontinued indicate that 75% of patients relapse within 6 to 24 months. Indefinite maintenance antipsychotic medication is generally recommended, and especially for patients who have had multiple prior episodes or 2 episodes within 5 years (APA [Lehman 2004]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26036922\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients; occurring in up to 18% of children. Use with caution in children and adolescents; adverse effects due to elevated prolactin levels have been observed; long-term effects on growth or sexual maturation have not been evaluated.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Paliperidone may cause a higher than normal weight gain in children and adolescents; monitor growth (including weight, height, BMI, and waist circumference) in pediatric patients receiving paliperidone; in adolescent trials, &le;19% of patients experienced a weight gain of &ge;7%; monitor weight and compare to standard growth curves.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Paliperidone may cause increases in metabolic indices (eg, serum cholesterol, triglycerides). Biannual monitoring of cardiometabolic indices after the first 3 months of therapy is suggested for atypical antipsychotics (Correll 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adolescents may experience a higher frequency of certain adverse effects than adults, particularly akathisia (4% to 17% vs 1% to 10%; dose dependent), somnolence (9% to 26% vs 1% to 12%), and vomiting (&le;11% vs 2% to 5%). Adolescents may experience some adverse effects not reported in adults, including amenorrhea, blurred vision, galactorrhea, gynecomastia, and tongue swelling.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Long-term usefulness of paliperidone should be periodically re-evaluated in patients receiving the drug for extended periods of time. Invega is an extended-release tablet based on the OROSA osmotic delivery system. Water from the GI tract enters through a semipermeable membrane coating the tablet, solubilizing the drug into a gelatinous form which, through hydrophilic expansion, is then expelled through laser-drilled holes in the coating.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Similar to adult experience, the American Academy of Child and Adolescent Psychiatry (AACAP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (AACAP [McClellan 2007]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9838448\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982393\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=87122&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Antipsychotic Agents may diminish the stimulatory effect of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Paliperidone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inducers of CYP3A4 (Strong) and P-glycoprotein: May decrease the serum concentration of Paliperidone. Management: Avoid using the 3-month extended-release injectable suspension (Invega Trinza) with inducers of both CYP3A4 and P-glycoprotein during the 3-month dosing interval if possible. If combination is necessary, consider using extended-release tablets.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May enhance the QTc-prolonging effect of Paliperidone. Itraconazole may decrease the metabolism of Paliperidone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antipsychotic Agents may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RisperiDONE: May enhance the adverse/toxic effect of Paliperidone. Management: Additive paliperidone exposure is expected with this combination.  Consider using an alternative combination when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Paliperidone. Management: Avoid using the 3-month extended-release injectable suspension (Invega Trinza) with inducers of both CYP3A4 and P-glycoprotein during the 3-month dosing interval if possible. If combination is necessary, consider using extended-release tablets.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May increase the serum concentration of Paliperidone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982378\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982379\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been observed in animal reproduction studies. Antipsychotic use during the third trimester of pregnancy has a risk for extrapyramidal symptoms (EPS) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. These effects may be self-limiting and allow recovery within hours or days with no specific treatment, or they may be severe requiring prolonged hospitalization.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Paliperidone may cause hyperprolactinemia, which may decrease reproductive function in both males and females. Paliperidone is the active metabolite of risperidone; refer to Risperidone monograph for additional information.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited and routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to a typical antipsychotic that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Healthcare providers are encouraged to enroll women 18 to 45 years of age exposed to paliperidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or http://www.womensmentalhealth.org/pregnancyregistry).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15513479\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure (including orthostatic) and heart rate, particularly during dosage titration; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms; growth, BMI, waist circumference, and weight (in adults, weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals; consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight); CBC with differential; liver enzymes in children (especially obese children or those who are rapidly gaining weight while receiving therapy); lipid profile; fasting blood glucose/Hgb A<sub>1c</sub> (prior to treatment, at 3 months, then annually); prolactin serum concentrations   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982398\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Paliperidone is considered a benzisoxazole atypical antipsychotic as it is the primary active metabolite of risperidone. As with other atypical antipsychotics, its therapeutic efficacy is believed to result from mixed central serotonergic and dopaminergic antagonism. The addition of serotonin antagonism to dopamine antagonism (classic neuroleptic mechanism) is thought to improve negative symptoms of psychoses and reduce the incidence of extrapyramidal side effects (Huttunen 1995). Similar to risperidone, paliperidone demonstrates high affinity to &alpha;<sub>1</sub>, &alpha;<sub>2</sub>, D<sub>2</sub>, H<sub>1</sub>, and 5-HT<sub>2A</sub> receptors and low affinity for muscarinic receptors. In contrast to risperidone, paliperidone displays nearly 10-fold lower affinity for &alpha;<sub>2</sub> and 5-HT<sub>2A</sub> receptors, and nearly three- to fivefold less affinity for 5-HT<sub>1A</sub> and 5-HT<sub>1D</sub>, respectively.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3982400\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Pharmacokinetic parameters in adolescent patients weighing &gt;51 kg were similar to adults; an increased drug exposure (23%) was observed in adolescent patient weighing &lt;51 kg compared to adults and was not considered clinically significant. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM: Slow release (Monthly: Begins on day 1 and continues up to 126 days; 3-month: Begins on day 1 and continues up to 18 months)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Oral: 487 L; Monthly IM: 391 L; 3-month IM: 1960 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 74% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP2D6 and 3A4 (limited role in elimination); minor metabolism (&lt;10% each) via dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 28%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 23 hours; 24 to 51 hours with renal impairment (CrCl &lt;80 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Monthly IM (following a single-dose administration): Range: 25 to 49 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3-month IM: Deltoid injection range: 84 to 95 days; Gluteal injection range: 118 to 139 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: ~24 hours; Monthly IM: 13 days; 3-month IM: 30 to 33 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80%; 59% as unchanged drug); feces (11%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5165183\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Invega Sustenna Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">39 mg/0.25 mL (0.25 mL): $500.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">78 mg/0.5 mL (0.5 mL): $1,000.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">117 mg/0.75 mL (0.75 mL): $1,500.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">156 mg/mL (1 mL): $2,001.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">234 mg/1.5 mL (1.5 mL): $3,002.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Invega Trinza Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">273MG/0.875ML (0.875 mL): $3,001.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">410MG/1.315ML (1.315 mL): $4,502.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">546MG/1.75ML (1.75 mL): $6,004.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">819MG/2.625ML (2.625 mL): $9,006.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Invega Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (30): $1,329.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (30): $1,329.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (30): $1,329.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 mg (30): $1,993.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Paliperidone ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (30): $916.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (30): $916.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (30): $916.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 mg (30): $1,375.29</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539984\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Inveda (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Inveda Sustenna (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Invega (AE, AR, AT, AU, BB, BE, BH, BR, CH, CN, CO, CY, CZ, DE, DK, EE, ES, GB, GR, HK, HR, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, MT, MY, NL, NZ, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, VN);</li>\n      <li>Invega SR (KR);</li>\n      <li>Invega Sustenna (AU, BR, CN, HK, ID, IL, JO, MY, NZ, PH, SG, TH, TW);</li>\n      <li>Inveha (UA);</li>\n      <li>Keplioon (JP);</li>\n      <li>Kseplion (UA);</li>\n      <li>Trevicta (IE);</li>\n      <li>Xeplion (CH, CY, CZ, DK, EE, ES, GB, HR, IE, IL, IS, LT, LU, LV, MT, NO, RO, SE, SI, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16529334\"></a>Canadian Psychiatric Association (CPA). Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13 Suppl 1):7S-57S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/16529334/pubmed\" target=\"_blank\" id=\"16529334\">16529334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23821039\"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23821039/pubmed\" target=\"_blank\" id=\"23821039\">23821039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Correll CU, Manu P, Olshanskiy V, et al, &quot;Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents,&quot; <i>JAMA</i>, 2009, 302(16):1765-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/19861668/pubmed\" target=\"_blank\" id=\"19861668\">19861668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ford RL, Sallam A, Towler HM. Intraoperative floppy iris syndrome associated with risperidone intake. <i>Eur J Ophthalmol</i>. 2011;21(2):210-211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/20853271/pubmed\" target=\"_blank\" id=\"20853271\">20853271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22834451\"></a>Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22834451/pubmed\" target=\"_blank\" id=\"22834451\">22834451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huttunen M. The evolution of the serotonin-dopamine antagonist concept. <i>J Clin Psychopharmacol</i>. 1995;15(1 Suppl 1):4S-10S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/7730499/pubmed\" target=\"_blank\" id=\"7730499\">7730499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invega (paliperidone) [prescribing information]. Titusville, NJ: Janssen; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invega Sustenna (paliperidone) [prescribing information]. Titusville, NJ: Janssen; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invega Trinza (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/17650054/pubmed\" target=\"_blank\" id=\"17650054\">17650054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15000267\"></a>Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2 Suppl):1-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/15000267/pubmed\" target=\"_blank\" id=\"15000267\">15000267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17195735\"></a>McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(1):107-125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/17195735/pubmed\" target=\"_blank\" id=\"17195735\">17195735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2013. Available at https://www.nice.org.uk/guidance/cg155.26065063</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. <i>N Engl J Med</i>. 2009;360(3):225-235.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/19144938 /pubmed\" target=\"_blank\" id=\"19144938 \">19144938 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15949658\"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/15949658/pubmed\" target=\"_blank\" id=\"15949658\">15949658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi: 10.1176/appi.ajp.2015.173501.27133416</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh J, Robb A, Vijapurkar U, et al, &quot;A Randomized, Double-Blind Study of Paliperidone Extended-Release in Treatment of Acute Schizophrenia in Adolescents,&quot; <i>Biol Psychiatry</i>, 2011, 70(12):1179-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/21831359/pubmed\" target=\"_blank\" id=\"21831359\">21831359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/17390261/pubmed\" target=\"_blank\" id=\"17390261\">17390261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stigler KA, Mullett JE, Erickson CA, et al, &quot;Paliperidone for Irritability in Adolescents and Young Adults With Autistic Disorder,&quot; <i>Psychopharmacology (Berl)</i>, 2012, 223(2):237-45<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22549762/pubmed\" target=\"_blank\" id=\"22549762\">22549762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 87122 Version 135.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50629645\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709193\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3981432\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5941023\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F15513469\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F15513477\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F3982430\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F3981434\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F15513478\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133437\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F3982397\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F15513470\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14087817\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3982388\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3982382\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3982383\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26036922\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9838448\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F3982393\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F3982378\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3982379\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15513479\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3982398\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F3982400\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5165183\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539984\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/87122|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=paliperidone-drug-information\" class=\"drug drug_general\">Paliperidone: Drug information</a></li><li><a href=\"topic.htm?path=paliperidone-patient-drug-information\" class=\"drug drug_patient\">Paliperidone: Patient drug information</a></li></ul></div></div>","javascript":null}